Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Zilucoplan Treatment of Severe MG Exacerbations Leading to Hospitalization of Participants With Acetylcholine Receptor Antibody Positive gMG

NCT07215949 is registered in ClinicalTrials.gov with Miriam Freimer as lead sponsor.

NCT NCT07215949
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07215949 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Zilucoplan Treatment of Severe MG Exacerbations Leading to Hospitalization of Participants With Acetylcholine Receptor Antibody Positive gMG
Lead sponsor
Miriam Freimer
Phase
Phase 3
Overall status
Recruiting
Start date
January 20, 2026
Completion date
April 1, 2028
Enrollment
15 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

generalized myasthenia gravis (gmg)